
Pfizer opens doors at newest gene therapy site in NC as part of $800M push into next-gen drugs
The Covid-19 pandemic has been an extremely profitable time for Pfizer, and the massive drugmaker is using that leverage to advance its portfolio writ large. Now, Pfizer’s emerging gene therapy biz will have some new elbow room as it continues to grow in the coming years.
Pfizer this week opened a $68.5 million gene therapy manufacturing facility in Durham, North Carolina, as part of a multi-year, $800 million plan to outfit its next-gen therapeutics business, the company said Wednesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.